Zhou Xin, Tian Wen, Gu Shenbiao, Rabinovitch Marlene, Nicolls Mark R, Snyder Michael P
Department of Genetics, Stanford University School of Medicine, Stanford, CA, USA.
Division of Pulmonary, Allergy, and Critical Care Medicine, Stanford University School of Medicine, Stanford, CA, USA.
Research (Wash D C). 2025 Apr 9;8:0669. doi: 10.34133/research.0669. eCollection 2025.
Pulmonary arterial hypertension (PAH) is a devastating disease characterized by perivascular inflammation, immune dysregulation, and vascular remodeling. Recent studies have unveiled a potential link between the gut microbiome and PAH pathogenesis, suggesting that microbial dysbiosis and increased intestinal permeability may contribute to the inflammatory pathology in PAH and ultimately disease progression. This perspective highlights the emerging evidence of the role of leaky gut in PAH, the interplay between microbiota-induced immune responses, and the activation of endogenous retroviruses like human endogenous retrovirus K. Understanding these complex interactions opens new interdisciplinary avenues for research and therapeutic interventions, potentially transforming PAH management through microbiome-targeted strategies.
肺动脉高压(PAH)是一种严重的疾病,其特征为血管周围炎症、免疫失调和血管重塑。最近的研究揭示了肠道微生物群与PAH发病机制之间的潜在联系,表明微生物群落失调和肠道通透性增加可能导致PAH的炎症病理,并最终导致疾病进展。这一观点强调了肠道渗漏在PAH中的作用、微生物群诱导的免疫反应之间的相互作用以及人类内源性逆转录病毒K等内源性逆转录病毒的激活等新出现的证据。理解这些复杂的相互作用为研究和治疗干预开辟了新的跨学科途径,有可能通过针对微生物群的策略改变PAH的管理。